REFERENCES
1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 2021;113:70-84.
3. Kawamoto T, Hara H, Morishita M, et al. Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma. Clin Exp Metastasis 2020;37:509-17.
4. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 1993;218:705-12.
5. Smith HG, Memos N, Thomas JM, Smith MJ, Strauss DC, Hayes AJ. Patterns of disease relapse in primary extremity soft-tissue sarcoma. Br J Surg 2016;103:1487-96.
6. Gonzalez MR, Bryce-Alberti M, Leon-Abarca JA, Pretell-Mazzini J. Brain metastases in patients with soft-tissue sarcomas: management and survival-a seer population-based cohort study. J Am Acad Orthop Surg Glob Res Rev 2021;5:1-10.
8. Walls GM, Zaidi SH, Fotiadis N, et al. Treatments and outcomes in oligometastatic soft tissue soft sarcoma - a single centre retrospective analysis. Anticancer Res 2021;41:5089-96.
9. Grilley-Olson JE, Webber NP, Demos DS, Christensen JD, Kirsch DG. Multidisciplinary management of oligometastatic soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2018;38:939-48.
10. Alexander J, Haight C. Pulmonary resection for solitary metastatic sarcomas and carcinomas; 1946. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20282935 [Last accessed on 12 Apr 2023].
11. Thomford NR, Woolner LB, Clagett OT. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg 1965;49:357-63.
12. Marudanayagam R, Sandhu B, Perera MT, et al. Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 2011;37:87-92.
13. Quiros RM, Scott WJ. Surgical treatment of metastatic disease to the lung. Semin Oncol 2008;35:134-46.
14. Margaritora S, Porziella V, D ‘Andrilli A, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardiothorac Surg 2002;21:1111-4.
15. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. Ann Thorac Surg 1986;42:134-8.
16. Younes RN, Gross JL, Deheinzelin D. Surgical resection of unilateral lung metastases: is bilateral thoracotomy necessary? World J Surg 2002;26:1112-6.
17. Mangiameli G, Cioffi U, Alloisio M, Testori A. Lung Metastases: current surgical indications and new perspectives. Front Surg 2022;9:884915.
18. Shiono S, Matsutani N, Hashimoto H, et al. Prospective study of recurrence at the surgical margin after wedge resection of pulmonary metastases. Gen Thorac Cardiovasc Surg 2021;69:950-9.
19. Schur S, Hoetzenecker K, Lamm W, et al. Pulmonary metastasectomy for soft tissue sarcoma-report from a dual institution experience at the Medical University of Vienna. Eur J Cancer 2014;50:2289-97.
20. Predina JD, Puc MM, Bergey MR, et al. Improved survival after pulmonary metastasectomy for soft tissue sarcoma. J Thorac Oncol 2011;6:913-9.
21. Lee K, Kang MC, Lee HW, et al. Pulmonary metastasectomy in adult patients with synovial sarcoma: a single-center experience. Korean J Thorac Cardiovasc Surg 2016;49:451-5.
22. Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 2017;15:78.
23. Nevala R, Jäämaa S, Tukiainen E, et al. Long-term results of surgical resection of lung metastases from soft tissue sarcoma: a single center experience. J Surg Oncol 2019;120:168-75.
24. Toussi MS, Bagheri R, Dayani M, Anvari K, Sheibani S. Pulmonary metastasectomy and repeat metastasectomy for soft-tissue sarcoma. Asian Cardiovasc Thorac Ann 2013;21:437-42.
25. Sardenberg RA, Figueiredo LP, Haddad FJ, Gross JL, Younes RN. Pulmonary metastasectomy from soft tissue sarcomas. Clinics 2010;65:871-6.
26. Chudgar NP, Brennan MF, Munhoz RR, et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg 2017;154:319-330.e1.
27. Wigge S, Heißner K, Steger V, et al. Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis. J Surg Oncol 2018;118:167-76.
28. Casson AG, Putnam JB, Natarajan G, et al. Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. J Surg Oncol 1991;47:1-4.
29. Shima Y, Horimi T, Ishikawa T, et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003;10:77-80.
30. Lang H, Nussbaum KT, Kaudel P, Frühauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg 2000;231:500-5.
31. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7; discussion 547.
32. Rehders A, Peiper M, Stoecklein NH, et al. Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J Surg 2009;33:111-7.
33. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117:1049-54.
34. Soyfer V, Corn BW, Shtraus N, et al. Single-institution experience of SBRT for lung metastases in sarcoma patients. Am J Clin Oncol 2017;40:83-5.
35. Loi M, Duijm M, Baker S, et al. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma. Radiol Med 2018;123:871-8.
36. Fuller BG. The role of radiation therapy in the treatment of bone and soft-tissue sarcomas. In: Musculoskeletal cancer surgery. Kluwer Academic Publishers; 1976. pp. 85-133. Available from: https://tumorsurgery.org/Portals/0/PDF/Textbooks/ch5.pdf [Last accessed on 15 Apr 2023].
37. Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol 2016;114:65-9.
38. Mehta N, Selch M, Wang PC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma 2013;2013:360214.
39. Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer 2015;51:668-74.
40. Chang UK, Cho WI, Lee DH, et al. Stereotactic radiosurgery for primary and metastatic sarcomas involving the spine. J Neurooncol 2012;107:551-7.
41. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys 2012;82:940-5.
42. Frakulli R, Salvi F, Balestrini D, et al. Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res 2015;35:5581-6.
43. Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res 2019;8:48-57.
44. Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014;90:1168-76.
45. Folkert MR, Bilsky MH, Tom AK, et al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. Int J Radiat Oncol Biol Phys 2014;88:1085-91.
46. Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 2000;191:184-90; discussion 190.
47. Blackmon SH, Shah N, Roth JA, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009;88:877-84; discussion 884.
48. Mohammed S, Basu A, Jilani A, et al. Primary squamous cell carcinoma of the toe masquerading as osteomyelitis: A case report aasim mohammed. Anticancer Res 2015;35:6704. Available from: https://ar.iiarjournals.org/content/anticanres/35/12/6695.full.pdf [Last accessed on 12 Apr 2023]
49. Withers HR, Lee SP. Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 2006;16:111-9.
50. Merimsky O, Kollender Y, Bokstein F, et al. Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2004;58:1468-73.
51. Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. Neurosurgery 2009;64:A54-9.
52. Thames HD, Suit HD. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 1986;12:687-91.
53. Qasem S. Biology and treatment of metastasis of sarcoma to the brain. Front Biosci 2016;8:233-44.
54. Salvati M, D' Elia A, Frati A, Santoro A. Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience. J Neurooncol 2010;98:373-7.
55. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
56. Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer 2017;5:78.
57. Vanni S, De Vita A, Gurrieri L, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol 2022;14:17588359221093973.
58. Palussière J, Italiano A, Descat E, et al. Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients. Ann Surg Oncol 2011;18:3771-7.
59. Falk AT, Moureau-Zabotto L, Ouali M, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol 2015;27:48-55.
60. Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001;12:187-93.
61. Harding D, Giles SL, Brown MRD, et al. Evaluation of quality of life outcomes following palliative treatment of bone metastases with magnetic resonance-guided high intensity focused ultrasound: an international multicentre study. Clin Oncol 2018;30:233-42.
62. Bongiovanni A, Foca F, Oboldi D, et al. 3-T magnetic resonance-guided high-intensity focused ultrasound (3-T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. Support Care Cancer 2022;30:5737-45.
63. Vincenzi B, Frezza AM, Schiavon G, et al. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 2013;3:6.
64. Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol 2019;20:6.
65. Jacobs EM. Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas. Cancer 1970;25:324-32.
66. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014;11:187-202.
67. O ‘bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
69. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
70. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415-23.
71. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin 2020;70:200-29.
72. Young RJ, Litière S, Lia M, et al. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta Oncol 2017;56:1013-20.
73. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol 2010;21 Suppl 7:vii270-6.
74. Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol 2022;18:3651-65.
75. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423-32.
76. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
77. Henry OS, Platoff R, Cerniglia KS, et al. Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): a narrative systematic review. Am J Surg 2023;225:268-74.
78. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 2011;16:682-93.
79. Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review. JAMA Oncol 2019;5:254-60.
80. Khan J, Ullah A, Waheed A, et al. Gastrointestinal stromal tumors (GIST): a population-based study using the SEER database, including management and recent advances in targeted therapy. Cancers 2022;14:3689.
81. Schaefer IM, DeMatteo RP, Serrano C. The GIST of advances in treatment of advanced gastrointestinal stromal tumor. Am Soc Clin Oncol Educ Book 2022;42:1-15.
82. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.
83. Rabban JT, Devine WP, Sangoi AR, et al. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 2020;77:100-11.
84. Recine F, De Vita A, Fausti V, et al. Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy. Front Oncol 2021;11:740676.
